Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H7N9 LAIV and Inactivated Vaccine in Adults 50-70
NCT02274545Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2014
- Primary completion
- May 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of H7N9 pandemic live attenuated influenza vaccine in Influenza A virus subtype H7N9 infection (H7N9), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of vaccine-related reactogenicity events at Day 37, Area under the curve of nasal virus shedding at Day 180 and 1 more. Started Oct 2014; status: completed.
02
Drugs
H7N9 pandemic live attenuated influenza vaccine
03
Conditions
Influenza A virus subtype H7N9 infection (H7N9)
Beyond the preview
Go deeper on NCT02274545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274545.